Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switches of migraine, nail fungus treatments may be next FDA challenges, Juhl predicts.

This article was originally published in The Tan Sheet

Executive Summary

RX-TO-OTC SWITCH OF MIGRAINE, NAIL FUNGAL INFECTION TREATMENTS may represent the next challenges for FDA in the area of switches, former Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD, University of Pittsburgh School of Pharmacy, suggested at a May 29 FDA meeting in Bethesda, Md. The meeting was convened by FDA's Office of Health Affairs to apprise health professional organizations about the Rx-to-OTC switch process and the agency's recent OTC labeling proposal.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel